Clinical characteristics of cryopyrin‐associated periodic syndrome and long‐term real‐world efficacy and tolerability of canakinumab in Japan: results of a nationwide survey
Takayuki Miyamoto,Kazushi Izawa,Sho Masui,Atsue Yamazaki,Yuichi Yamasaki,Tadashi Matsubayashi,Mayuka Shiraki,Hidenori Ohnishi,Junko Yasumura,Kawabe Tomohiro,Takako Miyamae,Tomoyo Matsubara,Naoya Arakawa,Takashi Ishige,Takumi Takizawa,Asami Shimbo,Masaki Shimizu,Naoki Kimura,Yuichi Maeda,Yuta Maruyama,Tomonari Shigemura,Junichi Furuta,Satoshi Sato,Hiroshi Tanaka,Miharu Izumikawa,Masahiro Yamamura,Toshio Hasegawa,Hiroshi Kaneko,Yasuo Nakagishi,Naoko Nakano,Yasunori Iida,Tamaki Nakamura,Hiroyuki Wakiguchi,Takayuki Hoshina,Toshinao Kawai,Kosaku Murakami,Shuji Akizuki,Akio Morinobu,Koichiro Ohmura,Katsuhide Eguchi,Motoshi Sonoda,Masataka Ishimura,Kenji Furuno,Momoko Kashiwado,Masaaki Mori,Kimito Kawahata,Koremasa Hayama,Kumiko Shimoyama,Natsuko Sasaki,Taisuke Ito,Hiroaki Umebayashi,Tae Omori,Seiko Nakamichi,Tomotsune Dohmoto,Yasuyuki Hasegawa,Hisashi Kawashima,Shojiro Watanabe,Yuichiro Taguchi,Haruna Nakaseko,Naomi Iwata,Hiroki Kohno,Taiki Ando,Yasuhiko Ito,Yuko Kataoka,Takako Saeki,Utako Kaneko,Ayako Murase,Seira Hattori,Tomo Nozawa,Kenichi Nishimura,Reiji Nakano,Misa Watanabe,Masato Yashiro,Tomonori Nakamura,Toshihiko Komai,Kentaro Kato,Yoshitaka Honda,Eitaro Hiejima,Atsushi Yonezawa,Kazuhisa Bessho,Satoshi Okada,Osamu Ohara,Junko Takita,Takahiro Yasumi,Ryuta Nishikomori,The Japan CAPS working group,Shigeaki Nonoyama,Kohsuke Imai,Shuichi Ito,Nobuo Kanazawa,Naotomo Kambe,Hidetoshi Takada,Takashi Yamazaki,Syuji Takei,Fumiko Ozaki,Tomoko Iehara,Tetsuo Kubota,Mitsuru Tsuge,Norimoto Kobayashi,Atsuo Taniguchi,Kiyoshi Kawakami,Kenji Nakagawa
DOI: https://doi.org/10.1002/art.42808
2024-01-26
Arthritis & Rheumatology
Abstract:Objective To assess the clinical characteristics of patients with cryopyrin‐associated periodic syndrome (CAPS) in Japan and evaluate the real‐world efficacy and safety of interleukin (IL)‐1 inhibitors, primarily canakinumab. Methods Clinical information was collected retrospectively, and serum concentrations of canakinumab and cytokines were analyzed. Results One‐hundred‐and‐one patients were included, with 86 and 15 carrying heterozygous germline and somatic mosaic mutations, respectively. We identified 39 mutation types, and the common CAPS‐associated symptoms corresponded with those in previous reports. Six patients (5.9% of all patients) died, with four of the deaths caused by CAPS‐associated symptoms. Notably, 73.7% of patients (100, 79.6, and 44.4% of familial cold autoinflammatory syndrome: FCAS, Muckle–Wells syndrome (MWS), and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem inflammatory disease (CINCA/NOMID), respectively) achieved complete remission with canakinumab, and early therapeutic intervention was associated with better auditory outcomes. In some patients, canakinumab treatment stabilized the progression of epiphysial overgrowth and improved height gain, visual acuity, and renal function. However, 23.7% of patients did not achieve inflammatory remission with crucial deterioration of organ damage, with two dying while receiving high‐dose canakinumab treatment. Serological analysis of canakinumab and cytokine concentrations revealed that the poor response was not related to canakinumab shortage. Four inflammatory non‐remitters developed inflammatory bowel disease unclassified during canakinumab treatment. Dual biologic therapy with canakinumab and anti‐ tumor necrosis factor‐α agents was effective for IBD‐ and CAPS‐associated symptoms not resolved by canakinumab monotherapy. Conclusions This study provides one of the largest epidemiologic datasets for CAPS. While early initiation of anti‐IL‐1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS following canakinumab treatment.
rheumatology